Results 111 to 120 of about 183 (135)

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

open access: yesEuropean Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino   +13 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, Volume 117, Issue 2, Page 320-337, August 2026.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta   +14 more
wiley   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 4, Page 795-806, August 2026.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala   +14 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Defining Cachexia in Children With Cancer in the United States: Developing a Framework to Inform Clinical and Research Practice

open access: yesJournal of Human Nutrition and Dietetics, Volume 39, Issue 4, August 2026.
ABSTRACT Background Cancer cachexia describes the muscle and weight loss, anorexia, and physical impairment common in certain adult cancers. No formal criteria exist to define paediatric cancer cachexia, making its clinical recognition and impact largely unknown. Using established undernutrition guidelines, criteria were developed to identify potential
Daniel V. Runco   +7 more
wiley   +1 more source

Dendritic cell‐specific hypoxia‐inducible factor‐1α deficiency protects mice from recurrent retroviral infection

open access: yesExperimental Physiology, Volume 111, Issue 8, Page 3843-3856, 1 August 2026.
Abstract Antigen‐processing and ‐presenting cells play a pivotal role in initiation of the antiviral immune response. The cellular adaption of dendritic cells to reduced oxygen and nutrition levels at the site of infection is regulated predominantly by the transcription factor complex hypoxia‐inducible factor‐1 (HIF‐1).
Timm Schreiber   +8 more
wiley   +1 more source

BCL‐2 and MCL1 co‐inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A‐rearranged acute lymphoblastic leukaemia

open access: yes
British Journal of Haematology, Volume 209, Issue 2, Page 786-792, August 2026.
Mawar Karsa   +19 more
wiley   +1 more source

B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics

International Journal of Molecular Sciences, 2022
Binoy Yohannan
exaly  

MLL (myeloid/lymphoid or mixed lineage leukemia)

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Jl Huret
exaly   +4 more sources

Home - About - Disclaimer - Privacy